Mattia D’Agostino, MD, University of Turin, European Myeloma Network, Turin, Italy, comments on how measurable residual disease (MRD) can be used to guide therapy in multiple myeloma. Dr D’Agostino explains that patients who are MRD-positive after treatment may benefit from changing therapy in order to achieve MRD negativity whereas MRD-negative patients may benefit from treatment de-escalation. However, this tool is not yet available in clinical practice. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.